Patents Assigned to Eisai R&D Management Co., Ltd.
  • Patent number: 11324805
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Patent number: 11327078
    Abstract: The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoko Ida, Takashi Obara, Emiko Yumoto
  • Patent number: 11325960
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11311530
    Abstract: Provided is a therapeutic agent for Lewy body disease comprising (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 26, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Yukio Ishikawa
  • Patent number: 11312720
    Abstract: A salt of the compound represented by formula (1) and crystals thereof having the potential to be used as drug substances for pharmaceutical products.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 26, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Taro Yamashita
  • Publication number: 20220117933
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Applicants: Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • Publication number: 20220112207
    Abstract: A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclization results with the formation of diazobicyclo[6.2.0]decane related compounds.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 14, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Branko MITASEV, Jiong YANG
  • Publication number: 20220081486
    Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
    Type: Application
    Filed: June 4, 2021
    Publication date: March 17, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
  • Patent number: 11267821
    Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 8, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiaki Ohashi, Yoshihiko Norimine, Tamaki Hoshikawa, Yu Yoshida, Yoshihisa Kobayashi, Nobuhiro Sato, Koji Hagiwara, Nobuaki Sato, Shinsuke Hirota, Takaaki Harada, Hikaru Yoshimura
  • Publication number: 20220048862
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Application
    Filed: October 27, 2021
    Publication date: February 17, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Publication number: 20220040168
    Abstract: This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of lenvatinib or a pharmaceutically acceptable salt thereof for use in treating hepatocellular carcinoma (e.g., unresectable hepatocellular carcinoma) according to any of the methods described herein. Particularly useful dosages and dose modifications upon the occurrence of an adverse event or events are also disclosed.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 10, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Toshiyuki Tamai
  • Publication number: 20220023275
    Abstract: An aqueous pharmaceutical formulation of a solubilizing agent with a pyridone compound that is useful as an inhibitor to non-NMDA receptors, particularly to the AMPA receptor is disclosed herein. In some embodiments the pyridone compound is supersaturated in aqueous solution at pH between 6 and 8. The formulations are particularly useful as intravenous injections.
    Type: Application
    Filed: December 16, 2019
    Publication date: January 27, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Geoffrey S. HIRD, Ganesh S.P. BOMMAREDDY, Anjali JOSHI, Ph.D., James MCSHANE
  • Publication number: 20220023285
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Application
    Filed: October 15, 2021
    Publication date: January 27, 2022
    Applicants: MERCK SHARP & DOHME CORP., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Andrew Evan DENKER, Yu KATO, Kimiyo TABATA, Yusaku HORI
  • Publication number: 20220017517
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 20, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yu YOSHIDA, Yoichi KITA, Makoto KOTAKE, Keiichi SORIMACHI, Toshiyuki OHFUSA, Takafumi MOTOKI, Taro ASABA
  • Patent number: 11219619
    Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: January 11, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsumi Yamaguchi, Hajime Shimizu, Satoshi Goda, Saori Miyano
  • Patent number: 11208429
    Abstract: The present invention provides a modified nucleic acid monomer compound having a specific backbone such as 2-ethylglycerol or methoxymethyl-1,3-propanediol backbone instead of a ribose or deoxyribose backbone of a nucleoside, and an oligonucleic acid analogue containing the monomer compound as at least one of building blocks. The oligonucleic acid analogue containing the nucleic acid monomer compound of the present invention allows provision of an oligonucleic acid analogue having excellent biological stability and/or target gene silencing activity.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshinori Takahashi, Yuta Suzuki
  • Patent number: 11186547
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: November 30, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Patent number: 11185554
    Abstract: The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 30, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alexander Bukreyev, Fabian Gusovsky, Patrick Younan, Michael Everson
  • Patent number: 11179387
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 23, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Publication number: 20210347779
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: November 11, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun ZHENG, Xiaojie ZHU, Hong DU, Maarten POSTEMA, Yimin JIANG, Jing LI, Robert YU, Hyeong-Wook CHOI, Jaemoon LEE, Francis G. FANG, Daniel CUSTAR